Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer

This study aims to evaluate the efficacy and safety of intravenous administration of vedacitinib combined with intravesical instillation of mitomycin in treating patients with high-risk NMIBC with HER2 expression. The goal is to provide a new treatment option for NMIBC patients, reduce the risk of tumor recurrence, decrease the proportion of radical bladder surgery, and improve the quality of life of patients.

Trial Details

NCT ID
NCT07646145
Phase
PHASE2
Sponsor
Shanxi Province Cancer Hospital
Status
RECRUITING
Cancer Type
Non-Muscle-Invasive Bladder Cancer
Interventions
  • Disitamab Vedotin
  • Mitomycin C (MMC)
Locations (sample)
  • Taiyuan, Shanxi, China|37.86944,112.56028

Key Eligibility Criteria

  • Voluntary participation, signing a written informed consent form;
  • The age on the date of signing the informed consent form should be no less than 18 years old, regardless of gender;
  • The subjects have completed the standard TURBT procedure before signing the informed consent form, and no obvious residual tumor lesions were found…
  • The postoperative pathology clearly diagnosed as non-muscle-invasive bladder cancer, and the main tissue component was more than 50% urothelial car…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Muscle-Invasive Bladder Cancer Trials on Trialify →